Ganciclovir

BRAND NAMES

Cytovene (and Cytovene-IV): The primary brand name for the injectable form used to treat cytomegalovirus (CMV) infections.

Zirgan: The brand name for ganciclovir ophthalmic gel (0.15%), used specifically for treating eye ulcers caused by the herpes virus.

Vitrasert: An older brand name for a ganciclovir intravitreal implant.

Ganzyk-RTU: A common brand name for ganciclovir injection.

MECHANISM OF ACTION

Ganciclovir is a guanine nucleoside analogue that inhibits viral DNA synthesis. After entering infected cells, it is first phosphorylated by viral enzyme (mainly CMV-encoded UL97 kinase) to ganciclovir monophosphate, then further converted by host cellular kinases to the active triphosphate form. Ganciclovir triphosphate competes with deoxyguanosine triphosphate for incorporation into viral DNA by viral DNA polymerase, leading to premature termination of DNA chain elongation and direct inhibition of viral DNA polymerase activity. This effectively blocks replication of cytomegalovirus (CMV) and other susceptible herpesviruses, with much greater selectivity for infected cells because activation depends largely on viral kinases.

PHARMACOKINETICS

Absorption: Poorly absorbed orally (5–9% bioavailability). Valganciclovir prodrug increases bioavailability to 60%.

Distribution: Rapid distribution phase (0.23 h), low protein binding (1–2%), volume of distribution is 0.74 L/kg.

Metabolism: Minimal. It is a cyclic analog of guanosine, converted intracellularly to ganciclovir triphosphate (active form).

Elimination: Primarily via renal excretion of unchanged drug (90%) through glomerular filtration and active tubular secretion.

PHARMACODYNAMICS

Ganciclovir is a synthetic analogue of 2′-deoxyguanosine that shows virustatic effects against herpesviruses, especially Cytomegalovirus (CMV). Its pharmacological action mainly depends on its activation within cells, after which it interferes with viral DNA synthesis and replication.

DOSAGE AND STRENGTH

The dosage and strength of Ganciclovir depend on the indication, route of administration, and patient factors like kidney function.

Common formulations and strengths:

• Injection (IV): 500 mg vial (powder for reconstitution)

• Oral capsule: 250 mg

• Typical dosing (general guidance):

1. For Cytomegalovirus (CMV) treatment (IV):

• Induction dose: 5 mg/kg every 12 hours for 14–21 days

• Maintenance dose: 5 mg/kg once daily (or 6 mg/kg 5 days/week)

2. Oral therapy (less commonly used now):

• 1000 mg (1 g) three times daily for induction

• 500 mg three times daily for maintenance

DRUG INTERACTIONS

Ganciclovir is associated with important drug interactions that can heighten toxicity, especially bone marrow suppression and kidney damage. Notable interactions include Zidovudine (leading to severe neutropenia and anemia), Imipenem-cilastatin (increased risk of seizures), Probenecid (which raises drug levels and toxicity), as well as other nephrotoxic medications. Careful monitoring of blood cell counts and renal function is essential, particularly when these drugs are used together.

FOOD INTERACTIONS

Ganciclovir has minimal clinically significant food interactions, but a few practical points are worth noting:

• Oral capsules: Food does not reduce effectiveness and may actually improve absorption slightly, so taking it with meals can be helpful and may reduce stomach discomfort.

• IV formulation: No food interactions, since it bypasses the digestive system.

• Hydration: Adequate fluid intake is important to help protect kidney function during therapy.

CONTRAINDICATIONS

Ganciclovir should not be used in patients who have a known hypersensitivity to Valganciclovir or Acyclovir. It should also be avoided in individuals with severe neutropenia, thrombocytopenia, or significant anemia, as it can further suppress bone marrow function and worsen these conditions.

SIDE EFFECTS

• Bone marrow suppression: This is the most serious and common effect, leading to reduced blood cell counts. Patients may experience fatigue, unusual bruising or bleeding, and a higher risk of infections.

• Gastrointestinal disturbances: Common symptoms include nausea, vomiting, diarrhea, abdominal discomfort, and loss of appetite.

• Neurotoxicity: May present as headache, dizziness, confusion, tremors, and occasionally seizures.

• Renal toxicity: There is a risk of kidney impairment, which may result in decreased urine output and increased creatinine levels.

• Reproductive and developmental effects: It may cause temporary or permanent infertility in both men and women and has the potential to cause birth defects.

• Other effects: Fever, skin rash, sweating, and pain or inflammation at the injection site (with IV use) can also occur.

OVERDOSE

An overdose of Ganciclovir can lead to serious and potentially life-threatening toxic effects. These include severe bone marrow suppression (such as leukopenia, anemia, and thrombocytopenia), acute kidney failure, and marked neurotoxicity, including seizures and coma. Immediate medical care is essential. Treatment typically includes hemodialysis to help remove the drug, along with supportive measures like adequate hydration and close monitoring.

TOXICITY

Ganciclovir toxicity mainly involves bone marrow suppression, leading to neutropenia, anemia, and thrombocytopenia, along with renal impairment and neurotoxic effects such as confusion or seizures. Gastrointestinal symptoms like nausea and diarrhea may also occur, and there is a risk of infertility and birth defects. Toxicity is more likely with high doses or impaired kidney function, so careful monitoring is essential.